MOUNTAIN VIEW, Calif. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday,

MOUNTAIN VIEW, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Jefferies London Healthcare

MOUNTAIN VIEW, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual

– Plans to Initiate Phase 2 Studies of IGM-2323 in Diffuse Large B-cell Lymphoma and Follicular Lymphoma – – Data from IGM-2323 Selected for Oral Presentation at 2021 ASH Annual Meeting – – IGM-8444 Successfully Completes Phase 1 Monotherapy Dose Escalation – – IGM-8444 Showed No Clinically

– John Shiver , Ph.D., and Tong-Ming Fu , M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler , M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif. , Oct.

MOUNTAIN VIEW, Calif. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference

MOUNTAIN VIEW, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences: Citi 16 th

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – MOUNTAIN VIEW, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.

MOUNTAIN VIEW, Calif. , July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto , M.D., Ph.D., F.A.C.P., to the role of Chief

Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021 MOUNTAIN VIEW, Calif. , June 03, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) a clinical-stage biotechnology company focused on creating and developing